Baulieu E E
INSERM U33, Bicêtre, France.
Hum Reprod. 1988 May;3(4):541-7. doi: 10.1093/oxfordjournals.humrep.a136741.
Anti-steroid hormones compete for hormone binding at the receptor level and prevent the hormonal response. A new parameter is proposed for explaining both anti-progesterone and anti-glucocorticosteroid activities of RU486, a synthetic derivative of high receptor affinity. It is based on its ability to stabilize the heterooligomeric 8S form of the glucocorticosteroid (in the chick oviduct system) and progesterone (in the rabbit uterus system) receptors. These 8S complexes involve the interaction of the approximately 94,000 and approximately 120,000 mol. wt receptors with the heat shock protein of the mol. wt approximately 90,000 (hsp 90). It is proposed that hsp 90 caps the DNA binding site of the receptor and that this would prevent it from binding to the DNA of hormone regulatory elements (HRE) and modifying transcription of regulated genes. In contrast, hormone agonists induce the dissociation of the oligomer, thus unmasking the functional DNA binding domain of the receptor. Whether other differences between agonist- and antagonist-receptor complexes are involved in the expression of hormone and anti-hormone effects also is discussed in this paper.
抗类固醇激素在受体水平上竞争激素结合位点,从而阻止激素反应。本文提出了一个新的参数来解释RU486(一种具有高受体亲和力的合成衍生物)的抗孕酮和抗糖皮质激素活性。这一参数基于其稳定糖皮质激素(在鸡输卵管系统中)和孕酮(在兔子宫系统中)受体的异源寡聚8S形式的能力。这些8S复合物涉及分子量约为94,000和120,000的受体与分子量约为90,000的热休克蛋白(hsp 90)的相互作用。本文提出hsp 90覆盖了受体的DNA结合位点,这将阻止其与激素调节元件(HRE)的DNA结合并改变受调控基因的转录。相反,激素激动剂诱导寡聚体解离,从而暴露受体的功能性DNA结合结构域。本文还讨论了激动剂和拮抗剂受体复合物之间的其他差异是否参与激素和抗激素效应的表达。